Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by overthelakeonlyon Jan 24, 2016 8:59am
157 Views
Post# 24488160

MACKIE RESEARCH REPORT

MACKIE RESEARCH REPORTIn their report, Mackie Research said: '' IF THE PIVOTAL RESULTS ARE SUCCESSFUL FOR PMX' WE EXPECT THIS STOCK TO GO THROUGH OUR CURRENT TARGET PRICE. WE ARE APPLYING A CONSERVATIVE 50% DISCOUNT RATE TO OUR ESTIMATED 2018 EPS ( FIRST YEAR OF ESTIMATED PMX SALES ) IN OUR VALUATION AND USING A 25X P/E MULTIPLE TO DERIVE OUR 12 MONTH TARGET PRICE OF $2.50. '' I really don't understand their target price because, if the pivotal results are not successful for PMX, the valuation will be -0- and if it is successful, in my opinion, we don't have to apply a 50% discount rate to the estimated 2018 eps and the target price should be $5.00. I think that their target price of $2.50 should be the share price before the trial results and $00 or $5.00 after the results. Meanwhile, if the results are between 10 and 15 absolute reduction in mortality, FDA could approve PMX and share price could be between $1.00 and $2.50 before the FDA decision. I am very confident that the results will be between 15 and 25% absolute reduction.
Bullboard Posts